Alembic Pharmaceuticals: Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic…
Alembic Pharmaceuticals (APLLTD) filed a disclosure titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP 0.3% / 0.1%". The company is valued at about ₹15,581 crore.
What happened
Alembic Pharmaceuticals (APLLTD) filed a disclosure with the exchanges on 17 October 2026 at 06:52 PM titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP 0.3% / 0.1%".
Company snapshot
Alembic Pharmaceuticals is a small-cap company in the Healthcare sector, with a market value of about ₹15,581 crore.
The stock last traded at ₹792.7, against a 52-week range of ₹635.8–₹998 (20.6% below the high).
Before this filing the shares had moved −3.9% over the month and −3.9% over three months. Average daily turnover over the last 20 sessions was about ₹19.62 crore.
Promoters held 69.87% at the end of Q1 FY27, up 0.13% points from the previous quarter. Foreign institutions owned 4.18% and domestic institutions 15.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,711 | 154.4 | 7.85 |
| Q2 FY26 | 1,910 | 184.7 | 9.4 |
| Q3 FY26 | 1,876 | 133 | 6.76 |
| Q4 FY26 | 1,848 | 201.5 | 10.31 |
| Q1 FY27 | 2,150 | 173.1 | 8.8 |
What history shows
This is not the company's first approval disclosure: BCEIE has 10 earlier filings of this kind on record since May 2026.
After those filings, the stock gained 1.6% on average the next trading day and was up 3.2% on average after five days (9 filings with price data).
Across 108 similar disclosures by other Healthcare companies, shares moved +0.3% on average the next day and +0.9% over five days; 49% of them rose the next day.
Market-wide, 1,511 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 16 Sept 2026 | Update on USFDA inspection conducted during 3rd March, 2025 to 7th… | +2.5% | +3.0% |
| 11 Sept 2026 | Successful completion of unannounced USFDA onsite inspection at… | −0.7% | +3.6% |
| 7 Sept 2026 | Approval | +2.2% | +3.2% |
| 28 Jul 2026 | Approval | −0.3% | −0.6% |
| 18 Jul 2026 | Approval | +1.0% | −1.3% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Alembic (APLLTD.NS) Sinks -0.72% as Volume Spikes on Downside 2026-10-11 - Volatility Term Structure
- APLLTD: US Pipeline Breadth Supports A Higher Fair Value
- Alembic Pharmaceuticals को प्रमुख oncology दवा के लिए USFDA से फाइनल अप्रूवल मिला; अधिक जानकारी यहां देखें।
- Alembic Pharmaceuticals: Gets USFDA Approval for Otic Suspension
- Alembic Pharmaceuticals secures USFDA approval for Ciprofloxacin and Dexamethasone otic suspension
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.